TITLE

55-year-old woman with menopausal symptoms and a family history of breast cancer

AUTHOR(S)
Mallin, Emily A.; Pavlicek, William
PUB. DATE
April 2008
SOURCE
Mayo Clinic Proceedings;Apr2008, Vol. 83 Issue 4, p485
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
The article presents the clinical study of a 55-year-old woman with menopausal symptoms and a history of breast cancer. Study reveals that the lifetime risks for a 55-year old woman with average risk factors are 1.5% and 10.2%. This indicates that the risk of the patient is not equal to that of other women of the same age with average risk. Moreover, the breast cancer risk assessment tool incorporates the Gail epidemiologic model, which includes multiple risk factors.
ACCESSION #
31718756

 

Related Articles

  • Effectiveness of Radiation Therapy for Older Women With Early Breast Cancer. Smith, Benjamin D.; Gross, Cary P.; Smith, Grace L.; Galusha, Deron H.; Bekelman, Justin E.; Haffly, Bruce G. // JNCI: Journal of the National Cancer Institute;5/17/2006, Vol. 98 Issue 10, p681 

    Background: Recent clinical trials have questioned the necessity of breast radiation therapy for older women with early breast cancer. However, the effectiveness of radiation therapy for older women in the community setting has not been addressed. Methods: We used the Surveillance, Epidemiology,...

  • HORMONE QUANDARY. Underwood, Anne // Newsweek;6/9/2003, Vol. 141 Issue 23, p64 

    Discusses the issue of hormone-replacement therapy. Increased risk of heart attack, stroke and breast cancer in aged women taking Prempo, a combined estrogen and progestin pill; Risk of dementia found in the Women's Health Risk Initiative Memory Study; Advice for postmenopausal women; Coping...

  • Fulvestrant (Faslodexâ„¢) in advanced breast cancer: clinical experience from a Belgian cooperative study. Patrick Neven; Robert Paridaens; Gino Pelgrims; Marc Martens; Alain Bols; Jean Goeminne; Anita Vindevoghel; Jan Demol; Barbara Stragier; Jacques De Greve; Christel Fontaine; Danielle Van Den Weyngaert; Dominique Becquart; Marleen Borms; Veronique Cocquyt; Rudy Van Den Broecke; Jean Selleslags; Ahmad Awada; Luc Dirix; Peter Van Dam // Breast Cancer Research & Treatment;May2008, Vol. 109 Issue 1, p59 

    Abstract  Fulvestrant (Faslodex™) is a new estrogen receptor (ER) antagonist with no agonist effects that is licensed for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer (ABC) who have progressed/recurred on prior antiestrogen therapy. The...

  • La recherche clinique dans le domaine du cancer du sein: état des lieux et perspectives. Gligorov, J.; Azria, D.; Belkacemi, Y.; Spielmann, M.; Namer, M. // Oncologie;Jun2009, Vol. 11 Issue 6, p319 

    Classification according to different biological features into subtypes has made breast cancer an increasingly complex and heterogeneous disease. With an estimated over 45,000 new breast cancer cases diagnosed in France every year, efforts in breast cancer research are focused, at both...

  • Caring for Older Women With Breast Cancer: Can Observational Research Fill the Clinical Trial Gap? Hillner, Bruce E.; Mandelblatt, Jeanne // JNCI: Journal of the National Cancer Institute;5/17/2006, Vol. 98 Issue 10, p660 

    The article focuses on providing care to older women with breast cancer. About half of the breast cancer patients in the United States are older women aged 65 years and above and their numbers are increasing each year. However, there is a lack of clinical trial data for the right treatment of...

  • Proportion of Invasive Breast Cancer Attributable to Risk Factors Modifiable after Menopause. Brian L. Sprague; Amy Trentham-Dietz; Kathleen M. Egan; Linda Titus-Ernstoff; John M. Hampton; Polly A. Newcomb // American Journal of Epidemiology;Aug2008, Vol. 168 Issue 4, p404 

    A number of breast cancer risk factors are modifiable later in life, yet the combined impact of the population changes in these risk factors on breast cancer incidence is not known to have been evaluated. The population attributable risk (PAR) associated with individual risk factors and the...

  • CANCER. PARK, ALICE // Time International (South Pacific Edition);2/14/2011, Vol. 177 Issue 6, p18 

    The article discusses a large British clinical trial of breast-cancer risk in menopausal women who use combination estrogen-and-progestin pills and estrogen-only pills for hormone therapy.

  • WHI: 11-year follow-up of breast cancer incidence and mortality.  // Reactions Weekly;11/6/2010, Issue 1326, p1 

    The article reports on the results from an 11-year follow-up of the Women's Health Initiative (WHI) trial aimed to determine the incidence and mortality of breast cancer in postmenopausal women who received combined hormone therapy.

  • Bioenvision plans new breast cancer studies with Modrenal.  // PharmaWatch: Cancer;January 2004, Vol. 3 Issue 1, p6 

    Reports on the plan of Bioenvision Inc. to conduct studies in Great Britain in pre-menopausal, pre-operative and post-menopausal women for the company's lead breast cancer treatment, Modrenal. Aim of the post-menopausal phase IV study; Clinical benefit rates of the drug.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics